logo
Share SHARE
FONT-SIZE Plus   Neg

Pharmacyclics Turns To Profit In Q1 - Quick Facts

Pharmacyclics Inc. (PCYC) reported that its first-quarter GAAP net income was $75.6 million, or $1.02 per share, compared to GAAP net loss of $14.5 million, or $0.21 loss per share in the year ago quarter.

The non-GAAP net income for the fiscal quarter was $78.8 million or $1.06 income per share, compared to a non-GAAP net loss of $12.4 million, or $0.18 per share last year.

Revenue for the quarter was $102.7 million, compared to $37,000 last year, an increase of approximately $102.7 million.

Revenue for the latest quarter consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement with Janssen Biotech, Inc.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.75 per share on revenues of $87.64 million for the quarter. Analysts' estimates typically exclude special items.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Everyone knows that the Federal Reserve will raise interest rates next Wednesday at the conclusion of its two-day policy meeting. After all, Fed speakers have been jawboning a rate hike over the past few weeks. With the markets reacting with eerie calm to Donald Trump's win, policy makers have no... GOP strategist Karl Rove has criticized U.S. President-elect Donald Trump's comments on aircraft maker Boeing Co.'s contract for a new Air Force One plane, saying they were inaccurate and de-stabled the stock of a major company. Air Force One is the official air plane for the U.S. President. Elon Musk's space transport company SpaceX has lost a satellite launch order from one of its customers due to the delay in its rocket launch schedule after one of its rockets exploded in September.
comments powered by Disqus
Follow RTT